Research leader appointed to head new cancer program

A national clinical research leader was appointed to head a new cancer program at UVM. The University of Vermont and Fletcher Allen Health Care have appointed Claire F. Verschraegen as professor and chief of hematology-oncology and interim director of the Vermont Cancer Center on Dec. 15, University Communications stated. “Dr. Verschraegen will bring a new dimension to our cancer program,” Dr. Melinda Estes president and CEO of Fletcher Allen Health Care, said. Verschraegen is a board-certified oncologist who specializes in rare cancers as well as the study of new anti-cancer drugs and treatments for solid tumors, University Communications stated. She will oversee cancer care and research at Vermont’s academic medical center, according to University Communications. Verschraegen was tenured at the University of New Mexico Cancer Center, where she oversaw the Clinical Protocol and Data Management Core, which received National Cancer Institute (NCI) designation in 2005, University Communications stated. “Dr. Verschraegen is recognized nationally as an accomplished clinician, investigator and mentor,” Dr. Frederick C. Morin III, dean of the University of Vermont College of Medicine, said.